MORGAN STANLEY PLC/CALL/ASTRAZENECA ADR/97.5/0.1/21.03.25 | Market Closed - Börse Stuttgart 02:14:30 2024-06-21 pm EDT | ||
| 0.154 EUR | +4.76% |
|
| Current month | +18.46% | ||
| 1 month | +62.11% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 24-06-21 | 0.154 | +4.76% |
| 24-06-20 | 0.147 | +8.09% |
| 24-06-19 | 0.136 | -8.11% |
| 24-06-18 | 0.148 | -8.64% |
| 24-06-17 | 0.162 | -2.99% |
Delayed Quote Börse Stuttgart
Last update June 21, 2024 at 02:14 pm EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | Morgan Stanley |
| WKN | MG39KK |
| ISIN | DE000MG39KK3 |
| Date issued | 2024-04-30 |
| Strike | 97.5 $ |
| Maturity | 2025-03-21 (273 Days) |
| Parity | 10 : 1 |
| Emission price | 0.14 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.176 € |
|---|---|
| Lowest since issue | 0.092 € |
| Spread | 0.005 € |
| Spread % | 3.16% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
157.5
USD
Average target price
174.4
USD
Spread / Average Target
+10.77%
- Stock Market
- Warrants
- Warrant
